Morphosys (ETR:MOR) received a €85.00 ($101.19) price target from research analysts at Berenberg Bank in a report released on Thursday. The firm currently has a “buy” rating on the stock. Berenberg Bank’s price target would indicate a potential upside of 8.63% from the company’s previous close.

Several other brokerages have also issued reports on MOR. Commerzbank set a €76.00 ($90.48) target price on shares of Morphosys and gave the stock a “buy” rating in a research report on Tuesday, November 7th. J P Morgan Chase & Co reiterated a “buy” rating and issued a target price on shares of Morphosys in a research report on Thursday, November 2nd. Goldman Sachs Group set a €55.00 ($65.48) target price on shares of Morphosys and gave the stock a “neutral” rating in a research report on Tuesday, September 19th. Deutsche Bank set a €90.00 ($107.14) target price on shares of Morphosys and gave the stock a “buy” rating in a research report on Monday, October 30th. Finally, Independent Research set a €77.00 ($91.67) target price on shares of Morphosys and gave the stock a “buy” rating in a research report on Thursday, September 7th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of €82.25 ($97.92).

Morphosys (ETR MOR) opened at €78.25 ($93.15) on Thursday. Morphosys has a 1 year low of €40.10 ($47.74) and a 1 year high of €83.78 ($99.74).

ILLEGAL ACTIVITY NOTICE: “Morphosys (MOR) PT Set at €85.00 by Berenberg Bank” was reported by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.watchlistnews.com/morphosys-mor-pt-set-at-85-00-by-berenberg-bank/1749040.html.

Morphosys Company Profile

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for Morphosys (ETR:MOR)

Receive News & Ratings for Morphosys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphosys AG and related companies with Analyst Ratings Network's FREE daily email newsletter.